Welcome to the ACTIV‑6 study
Working together to help people with COVID-19 feel better faster.
For more information or to report a concern, call 833-385-1880 or complete this form.
Welcome to ACTIV‑6!
Thank you for your interest in ACTIV-6. We are truly grateful to clinical trial participants who help advance science and our understanding of treatments for COVID-19. Learn more from Dr. Susanna Naggie, ACTIV-6 principal investigator, in this video.
How the Study Works
ACTIV-6 is a unique study that allows participants to take part from anywhere in the U.S. There are no required clinic visits or procedures, and study medications are mailed directly to you. Participation involves taking the study medication and keeping track of symptoms by completing surveys online or by phone.
Why This Study Is Important
Vaccines are available, but access is limited in some areas and new, more transmissible variants of the virus have emerged in the U.S. People are still getting sick, and many remain at risk for the disease.
Results from ACTIV-6 will help researchers understand how existing medications can improve symptoms and limit hospitalizations for people with mild-to-moderate COVID-19.
Study Eligibility
ACTIV-6 may be for you if:
- You are 30 years old or older.
- Tested positive for COVID-19 within the past 10 days.
- Have at least 2 COVID-19 symptoms for 7 days or less. Symptoms include fatigue, difficulty breathing, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, and/or new loss of sense of taste or smell.
Medications in the ACTIV-6 Study
ACTIV-6 is evaluating repurposed medications for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are already approved by the U.S. Food and Drug Administration for other indications. The study is now testing these medications:
- Metformin (open): an oral medication commonly used to treat diabetes
- Montelukast (closed): an oral anti-inflammatory medication commonly used to treat chronic asthma and for relief of seasonal
allergy symptoms - Fluticasone (closed): an inhaled steroid commonly prescribed to prevent and treat asthma
- Fluvoxamine (closed): a selective serotonin reuptake inhibitor (SSRI), often prescribed for depression
- Ivermectin (closed): a medication used to treat parasitic infections
These medications can be shipped anywhere in the United States at no cost to participants.
You can participate from anywhere in the United States!
ACTIV-6 is a nationwide double-blind study expected to enroll up to 15,000 participants. People can participate in ACTIV-6 from anywhere in the United States via the ACTIV-6 website or call center, 833-385-1880.
Please note: You may participate from anywhere in the United States, even if there is no site near your location.
Enroll Today!
Fill out the screening form to have a study team member contact you,
or call 833-385-1880 to speak with a study team member.
Together, we can change the future
of COVID-19 treatment.